Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bioshield legislation

This article was originally published in The Gray Sheet

Executive Summary

Sen. Judd Gregg (R- N.H.) plans Senate HELP Committee hearings this fall to consider follow-up legislation to the Project Bioshield Act (S 15) to address, among other topics, corporate liability for products developed under the program. The legislation, approved in the House July 14 following Senate passage May 19, secures $5.6 bil. in funding over the next five years for development of diagnostic and therapeutic countermeasures against bioterrorism agents and ensures rapid regulatory review, when necessary. AdvaMed has backed the Bioshield provisions since the concept was unveiled during President Bush's 2003 State of the Union address. The association also has maintained the importance of liability protection for products used in emergency...

You may also be interested in...



Neuroscience Challenges Oncology For Top Spot In CDER’s 2019 Novel Approvals

Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.

In Case You Missed It … News On China Patents, EMA Chief, And More

We clean out your Martin Luther King Day inbox so you don't have to.

At Muted J.P. Morgan, Focus Is Execution, But US Pricing Is Persistent Overhang

Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.

UsernamePublicRestriction

Register

MT020566

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel